Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisRisk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Skin cancer in organ transplant recipients: more than the immune system.Tumor necrosis factor inhibitors - state of knowledge.APLAR rheumatoid arthritis treatment recommendations.Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumabMalignancy rates in patients with rheumatoid arthritis treated with tocilizumab.Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Cancer risk in immune-mediated inflammatory diseases (IMID).Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Adverse effects of golimumab in the treatment of rheumatologic diseases.Infectious and malignant complications of TNF inhibitor therapy in IBD.Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure.Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.Management of severe complications in Behçet's disease with TNF inhibitors.Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.Coexistent malignant conditions in rheumatoid arthritis - A population-based cross-sectional study.Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.Intertoe Squamous Cell Carcinoma Developed in a Patient with Rheumatoid Arthritis under Etanercept Therapy.Prevalence of human Papillomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors.Epidermal PPARγ influences subcutaneous tumor growth and acts through TNF-α to regulate contact hypersensitivity and the acute photoresponse.Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients
P2860
Q24193535-BD8E8149-184B-438E-B852-7C763CAF70F7Q26774173-029CD050-2EB0-4AA3-B2FB-967ED5A77E79Q30240212-4C380622-5D23-4742-8F87-D14BD0F2C0EAQ33923227-0E9B4F6E-C4C1-4BDD-9C8B-98402AA815CAQ34974335-59FBFEA8-742C-4F49-8CCD-5516CF48B4BEQ35762912-AA341AC0-F13D-4EEE-A787-51E9E51A903DQ35842876-3EFDD834-B446-451B-ACD1-193F36D21792Q36714237-73A4344A-9CD8-4691-8A9C-0AC847484E17Q36919914-A3156458-E71F-4161-B2EF-2CBA22350640Q37100264-CA8D6629-86D3-46D2-831D-B738A4C09769Q37153407-6216454D-9475-4C16-8EA5-B47DB98ECBCFQ38099248-C23BFFEA-225B-450A-90C9-B5EE977A6CEDQ38132273-1699B0EE-8C87-4D29-B83D-DDD5A5EF587BQ38138343-244FA07F-10A9-4B34-8539-51E0F7C1C2D8Q38160896-6AFA4639-5BB2-412A-8B25-9A343744B589Q38161956-B05C7FDF-0FEE-41A6-AF08-F01CDF3E8393Q38180195-8D371AEB-9EC5-47D1-8ADC-0C55B650D940Q38203622-30634A24-2D5C-4B91-AB4A-AA4B8AF45993Q38258440-591AAC37-DEBA-48E6-8DA9-0F9F7DE8E9F1Q38445319-5D1DCF05-97A3-4150-902B-D131F83C098CQ38611360-6BF4B940-4404-459D-AA76-3739A576DAB7Q38663608-00961022-1DE3-449D-8470-ACFA469CC2E4Q38786414-7CAC2346-8AB7-46E8-A9AD-10D598CE5C05Q39053105-47C0EC21-8CD4-4C77-942F-48EABC3D6236Q40354684-98F35F11-BCA8-429D-9F72-C1D6BAC3A6FFQ40383687-C2A3986E-E239-42FD-8E7B-73BC86FBD4C3Q42083786-50ACD0D2-708B-456E-9A13-D872FC7D441EQ42256956-C90BF767-4893-4319-84DD-98C455DE8A6AQ47139765-AE67A22C-5295-4C34-B3ED-395EA17C6156Q48089393-88D4AD22-25BD-4D74-A6C8-E18B34D535B2Q57767895-2321BE4C-DF48-4FC4-BC88-887E6C9D3EA5
P2860
Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@ast
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@en
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@nl
type
label
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@ast
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@en
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@nl
prefLabel
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@ast
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@en
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Cancer risk of anti-TNF-α at r ...... reat and per protocol analyses
@en
P2093
Agnès Sommet
Guillaume Moulis
Johana Béné
Laurent Sailler
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0048991
P407
P577
2012-01-01T00:00:00Z